Safe Supply Announces Sale of NIRLAB Drug Analysis Device to Far North Resources Inc., Advancing Indigenous-Led Community Safety and Rapid Drug Identification
Safe Supply Streaming Co Ltd. (CSE: SPLY) (OTCQB: SSPLF) (FSE: QM4) ("Safe Supply" or the "Company") sale of its NIRLAB drug‑analysis device to Far North Resources Inc. is a targeted but strategically meaningful commercial step for its health and safety technology platform. It offers early commercial validation that NIRLAB can attract paying customers in real‑world settings, moving the company beyond pilots toward a recurring business model.
The transaction reflects rising demand for rapid, on‑site drug identification tools as communities confront the risks of an unpredictable, unregulated drug supply. NIRLAB’s portable, fast, and non‑destructive capabilities position it well for remote and underserved regions where timeliness, accessibility, and trust are critical.
From a market perspective, this sale reinforces Safe Supply’s ability to demonstrate real‑world adoption, even at modest scale. Importantly, the partnership with an Indigenous‑led organization underscores an emerging distribution pathway that aligns technology deployment with community‑driven safety initiatives, potentially improving uptake and long‑term engagement.
While the transaction itself is unlikely to be financially transformative in isolation, it serves as proof of concept for broader commercialization. The key execution focus going forward will be converting similar opportunities into a steady pipeline of device placements, service agreements, and recurring revenue streams.
Overall, the announcement signals incremental progress in validating Safe Supply’s business model, with social impact and commercial relevance increasingly converging as the company builds credibility in a sensitive but growing market segment.
About Safe Supply Streaming Co Ltd.
Safe Supply Streaming Co Ltd. (CSE: SPLY) (OTCQB: SSPLF) (FSE: QM4) is a publicly traded company building and backing innovations in healthcare, wellness, and emerging technologies. Through acquisitions, partnerships, and growth capital, the Company assembles a diversified portfolio that leverages data, science, and digital platforms to improve access and outcomes at scale. Operating at the intersection of public health and technology, Safe Supply supports evidence-informed solutions to urgent societal needs. Its wholly owned subsidiaries, including Safety Strips Tech Corp. and Drug Lab 118 Ltd., develop proprietary rapid-testing technologies-such as single-use presumptive fentanyl and drink-spiking detection products.
For more information, please visit www.safesupply.com.
ArcStone Financial Pulse Team
Stay informed with the latest market trends and investment insights from ArcStone Securities and Investments Corp. Subscribe to our newsletter for more detailed reports and analysis.
Disclaimer and Forward-Looking Statements
The information contained herein is provided by ArcStone Securities and Investments Corp. ("ArcStone") for informational purposes only. It is not, and under no circumstances should it be construed as, an offer to sell or a solicitation of an offer to buy any securities or other financial instruments in any jurisdiction.
Certain statements contained herein may constitute "forward-looking statements" within the meaning of applicable Canadian and U.S. securities laws. Forward-looking statements are based on current expectations, estimates, and assumptions that involve known and unknown risks and uncertainties which may cause actual results or developments to differ materially from those expressed or implied. These statements often include words such as "anticipate," "believe," "expect," "intend," "may," "plan," "project," "should," "target," or similar expressions. Readers are cautioned not to place undue reliance on such statements, which speak only as of the date made. Except as required by law, ArcStone undertakes no obligation to update or revise any forward-looking information.
This content is not intended as investment advice or a recommendation to buy or sell any security and does not take into account the investment objectives, financial situation, or needs of any individual. Investors should consult their own professional advisors before making any investment decisions.
ArcStone Securities and Investments Corp. is not a registered broker-dealer and does not provide investment advice or recommendations. All registrable activities in the United States are conducted through ArcStone Securities, LLC and Kingswood US, both FINRA-registered broker-dealers. The issuer featured in this article (the "Company") is either a current client of ArcStone or a client through one of its affiliates. ArcStone and/or its affiliates have received or expect to receive cash, stock, stock options, warrants, and/or Restricted Stock Units (RSUs) for the provision of corporate advisory, investor relations, digital media, or capital markets consulting services to the Company over a twelve (12) month period. This relationship represents a potential conflict of interest, as ArcStone may be perceived to have an incentive to present the Company in a favorable light. The principals, directors, officers, employees, and related entities of ArcStone and its affiliates may, from time to time, own, buy, or sell securities or derivatives of the Company or its affiliates.
